Why we use tesamorelin instead of HGH.
If you've been pitched HGH at another clinic, this is the conversation you should have had first.
You probably don't need HGH. You need GH signaling.
Patients arrive at Limitless having read about — or been pitched — human growth hormone (HGH). The pitch is appealing: leaner body, better recovery, sharper energy, the "anti-aging" pitch in three letters. The problem is that injecting HGH is the wrong way to get there for almost everyone who is not formally GH-deficient.
What you actually want is the downstream effect of healthy GH pulses — not the supraphysiologic hormone bath that comes from injecting recombinant HGH twice a day. Tesamorelin is the cleaner path. It is a GHRH analog. It tells your own pituitary to release growth hormone the way it did when you were thirty — in pulses, with feedback regulation intact.
It is the difference between asking your pituitary to do its job, and replacing it.
What's actually happening in your body.
HGH (recombinant growth hormone)
You inject the finished hormone directly. Blood GH levels rise, stay high for hours, and your hypothalamus turns off its own GHRH signal in response. Your endogenous pulse architecture flattens. IGF-1 rises in proportion to the dose, often into supraphysiologic range. Insulin resistance increases. Edema, joint stiffness, and carpal tunnel symptoms are common. Long-term oncologic and cardiovascular risk in non-GH-deficient adults is unsettled and concerning enough that most academic endocrinologists will not prescribe it for "optimization" indications.
Tesamorelin (GHRH analog)
You inject a 44-amino-acid molecule that binds GHRH receptors on the pituitary. The pituitary then releases growth hormone in its natural pulsatile pattern. The hypothalamus retains control. Somatostatin (the brake) still works. IGF-1 rises modestly into the upper-physiologic range — useful, not excessive. Insulin resistance risk exists but is dose-dependent and monitorable. Visceral fat — the fat that actually drives cardiometabolic disease — preferentially shrinks.
One pathway preserves the regulatory architecture your endocrine system spent evolution perfecting. The other overrides it.
The same goal, two very different tools.
| Tesamorelin | Exogenous HGH | |
|---|---|---|
| Mechanism | Stimulates your pituitary | Replaces what your pituitary does |
| Endogenous feedback | Intact | Bypassed |
| FDA approval | Yes (HIV lipodystrophy) | Narrow indications only — "anti-aging" use is not approved and largely not legal |
| Insulin resistance risk | Modest, monitorable | Higher, sustained |
| Visceral fat selectivity | High | Less selective |
| Long-term safety in optimization use | Limited but favorable so far | Unsettled; concerning signals |
| Compounding legal status (post Apr 23, 2026) | Yes — via licensed 503A/503B | No — not for non-approved indications |
| On the Limitless menu? | Yes | No |
Why it matters that this is even a legal question.
Federal law is clear: human growth hormone may be prescribed only for specific approved indications — adult GH deficiency, pediatric short stature, AIDS-associated wasting, and a few others. Prescribing HGH for "anti-aging," "optimization," or weight loss in adults without documented deficiency is not just outside the standard of care. It is, in many circumstances, illegal under the FDCA. Clinics that pitch HGH casually are taking a regulatory posture that we are not willing to take — and that we believe most patients, once informed, would not want their physician to take either.
Tesamorelin sits in a different regulatory category. It is FDA-approved (for HIV lipodystrophy), routinely used off-label for visceral adiposity under physician judgment — the way many approved drugs are — and now legally compoundable through licensed 503A/503B pharmacies following the April 23, 2026 reclassification. The path is clean.
The question we'll actually answer in your consult.
You don't have to take a position on growth hormone biology. You're paying us to take that position for you. What you should leave your consult understanding is:
- Whether your visceral adiposity, lab pattern, and goals make tesamorelin a fit.
- What we expect to see at 12 weeks, 26 weeks, and beyond.
- What we will monitor, how often, and what would cause us to dose-reduce or stop.
- The 26-week framework — courses with planned reassessment, not indefinite daily dosing.
- Why we are not prescribing HGH and what would have to be true for that to change.
Physician summary of the 2026 pooled meta-analysis — five RCTs, −27.7 cm² VAT, +1.42 kg lean mass, and the emerging cognitive endpoint that distinguishes tesamorelin from indiscriminate GH stimulation. Tesamorelin — what the 2026 meta-analysis actually shows →
Bring the question to consult.
If you've been pitched HGH and want a physician's read on the mechanism, the data, and the alternatives — that conversation is exactly what we do.
Request a consultation